New Breast Cancer Treatment Adds 15 Months Without Disease

Women fighting a particularly aggressive form of breast cancer just got a game-changing new weapon in their corner.

The FDA has approved a new treatment combination for patients with double-positive metastatic breast cancer that keeps the disease from progressing for over 15 months longer than standard therapy alone. The approval came after results from the PATINA study showed remarkable improvements for women whose cancer had stopped responding to traditional treatments.

Dr. Otto Metzger at Dana-Farber Cancer Institute led the international trial involving patients across the United States, France, Germany, Italy, Spain, Australia, and New Zealand. His team found that adding the drug palbociclib to standard therapy extended the median time without disease progression to 44.3 months, compared to just 29.1 months with standard treatment alone.

About 10 percent of all breast cancers are the double-positive type, meaning they test positive for both hormone receptors and a protein called HER2. This combination makes the cancer especially tricky to treat because it often becomes resistant to standard therapies, even when patients respond well initially.

The new treatment targets this resistance head-on. Patients in the study who had already been treated with anti-HER2 therapy received the new three-drug combination during their maintenance phase, the period after initial treatment when doctors work to keep cancer from returning or spreading.

The Ripple Effect

This approval means oncologists now have solid evidence to support a treatment approach that can give their patients significantly more quality time. For women facing metastatic breast cancer, an extra 15 months without their disease progressing can mean more time with family, more celebrations, and more hope for future breakthroughs.

The study's success also demonstrates the power of international collaboration in cancer research. Six cancer research groups across multiple continents worked together to make this breakthrough possible, showing how sharing knowledge across borders speeds up progress for patients everywhere.

The findings were published in the New England Journal of Medicine and presented at the San Antonio Breast Cancer Symposium in December 2024, giving doctors worldwide immediate access to this life-extending approach. Patients can now talk with their oncologists about whether this new combination therapy might be right for their treatment plan.

For thousands of women diagnosed with double-positive breast cancer each year, this approval transforms a difficult diagnosis into one with more options and more time.